Kenvue Inc. (NYSE:KVUE) Given Consensus Recommendation of “Hold” by Brokerages

Kenvue Inc. (NYSE:KVUE) has earned an average recommendation of “Hold” from the sixteen brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $24.85.

KVUE has been the topic of a number of analyst reports. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Sanford C. Bernstein assumed coverage on Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. Royal Bank of Canada decreased their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Finally, William Blair assumed coverage on Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock.

Institutional Investors Weigh In On Kenvue

A number of hedge funds have recently bought and sold shares of KVUE. Empirical Finance LLC bought a new position in Kenvue during the 3rd quarter worth approximately $336,000. UniSuper Management Pty Ltd bought a new position in Kenvue during the 3rd quarter worth approximately $35,544,000. Howland Capital Management LLC bought a new position in Kenvue during the 3rd quarter worth approximately $7,764,000. Citizens Business Bank bought a new position in Kenvue during the 3rd quarter worth approximately $2,507,000. Finally, Fifth Third Bancorp lifted its holdings in Kenvue by 35.3% during the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after buying an additional 72,435 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 1.1 %

KVUE stock opened at $19.36 on Friday. The firm has a 50-day simple moving average of $19.84 and a two-hundred day simple moving average of $20.15. Kenvue has a one year low of $17.82 and a one year high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. Kenvue’s revenue was down 2.7% compared to the same quarter last year. As a group, research analysts forecast that Kenvue will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were paid a $0.20 dividend. The ex-dividend date was Tuesday, February 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.13%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.